Giulio Leone

Giulio Leone

Auto-generated profile, based on publicly available information

Giulio Leone

Department of Orthopaedic Surgery, San Gerardo Hospital, Monza, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2018 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
Costantino ErraniCostantino Errani
Costantino Errani
STShinji Tsukamoto
Shinji Tsukamoto
GLGiulio Leone
Giulio Leone
ARAlberto Righi
Alberto Righi
MAManabu Akahane
Manabu Akahane
DDDavide Maria Donati
Davide Maria Donati
Background: Recent clinical studies have suggested that denosumab is associated with tumor response and reduced surgical morbidity in patients with giant-cell tumor of bone (GCTB). We therefore evaluated the recurrence-free survival rate of patients who had GCTB in an extremity and were treated with surgery and denosumab, to determine the influence of denosumab and clinical factors on the risk of local recurrence. Methods: We retrospectively reviewed the medical records of 408 patients treated for GCTB in an extremity in a single institution from 1990 through 2013. Two hundred and forty-seven patients underwent curettage (intralesional surgery) with a high-speed burr, and 161 underwent resection. Phenol adjuvant was used in 221 of the 247 patients who had curettage. We also reviewed the medical records of 30 patients treated surgically (25 with curettage and 5 with resection) and with denosumab from 2010 through 2013 and compared their clinical results with 378 historical control subjects. The overall minimum duration of follow-up was 24 months. Results: The local recurrence rates were 60% (15) of 25 patients treated with curettage and denosumab and 16% (36) of 222 patients treated with curettage alone. The joint preservation rates were 80% (20) of 25 patients treated with curettage and denosumab and 94% (209) of 222 patients treated with curettage alone. Univariate and multivariable analyses showed that denosumab was the only independent factor associated with a poor prognosis when recurrence-free survival and joint preservation were considered. The overall median duration of follow-up was 85.6 months (interquartile range, 54.3 to 125.1 months). Viable tumor was present in all 30 specimens from patients treated with denosumab. Conclusions: There was a higher rate of recurrence in the cohort exposed to denosumab. Because there were substantial differences in the cohorts and randomization was not applied, however, causation could not be evaluated. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

6 June 2017 in European Journal of Orthopaedic Surgery & Traumatology
Verified
Journal Article
Closed access
PDF file
Costantino ErraniCostantino Errani
Costantino Errani
STShinji Tsukamoto
Shinji Tsukamoto
GLGiulio Leone
Giulio Leone
MAManabu Akahane
Manabu Akahane
LCLuca Cevolani
Luca Cevolani
DDDavide Maria Donati
Davide Maria Donati

7 February 2019 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Shinji TsukamotoShinji Tsukamoto
Shinji Tsukamoto
Andreas F. MavrogenisAndreas F. Mavrogenis
Andreas F. Mavrogenis
PTPiergiuseppe Tanzi
Piergiuseppe Tanzi
GLGiulio Leone
Giulio Leone
ARAlberto Righi
Alberto Righi
Costantino ErraniCostantino Errani
Costantino Errani

8 June 2019 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
MBMarco Bigoni
Marco Bigoni
MTMarco Turati
Marco Turati
GLGiulio Leone
Giulio Leone
ACAgostino Dario Caminita
Agostino Dario Caminita
FDFabio D’aNgelo
Fabio D’aNgelo
GZGiovanni Zatti
Giovanni Zatti

11 August 2018 in International Orthopaedics
Verified
Journal Article
Closed access
PDF file
Shinji TsukamotoShinji Tsukamoto
Shinji Tsukamoto
Andreas F. MavrogenisAndreas F. Mavrogenis
Andreas F. Mavrogenis
GLGiulio Leone
Giulio Leone
ARAlberto Righi
Alberto Righi
MAManabu Akahane
Manabu Akahane
Costantino ErraniCostantino Errani
Costantino Errani

13 September 2019 in European Journal of Orthopaedic Surgery & Traumatology
Verified
Journal Article
Closed access
PDF file
STShinji Tsukamoto
Shinji Tsukamoto
Andreas F. MavrogenisAndreas F. Mavrogenis
Andreas F. Mavrogenis
PTPiergiuseppe Tanzi
Piergiuseppe Tanzi
GLGiulio Leone
Giulio Leone
MAManabu Akahane
Manabu Akahane
Costantino ErraniCostantino Errani
Costantino Errani